The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Lectures Included

• Disease State Network Year-in-Review: PGAN
• The New Biology of Pheochromocytomas
• Adrenal Imaging Strategies: Which and When
• Neuroendocrine Tumors: Current Therapeutic Strategies and Views for Neuroendocrine Tumors

Learning Objectives

Upon completion of the activity, participants should be able to:

• Evaluate the latest clinically-relevant articles on adrenal, pituitary and gonad disorders
• Outline the newest discoveries regarding functional imaging of pheochromocytoma and paraganglioma, including newest imaging guidelines and treatment options related to metastatic tumors focusing on personalized medicine
• Recognize the imaging features of an adrenal adenoma from a non-adenoma, pheochromocytomas and adrenal cortical carcinomas
• Recognize the clinical features and current safety and efficacy of medical management of functional neuroendocrine tumors

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

• Michael Blake, MD - Attending Radiologist Massachusetts General Hopsital: Nothing to disclose
  
• Adriana Ioachimescu, MD, PhD, FACE - Professor of Medicine (Endocrinology) and Neurosurgery Emory University: Chiasma (Self: 2 financial relationships declared - Consulting Fees (e.g., advisory boards), Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received); Chiasma, currently Amryt (Self: 3 financial relationships declared - Consulting Fees (e.g., advisory boards), Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Multicentric phase III trial); HRA Pharma (Self: 1 financial relationship declared - Consulting Fees (e.g., advisory boards)); Ipsen (Self: 1 financial relationship declared - Consulting Fees (e.g., advisory boards)); Novartis (Self: 2 financial relationships declared - Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Multicentric phase III trial); Pfizer (Self: 2 financial relationships declared - Consulting Fees (e.g., advisory boards), Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received) Recordati (Self: 2 financial relationships declared - Consulting Fees (e.g., advisory boards), Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received); Strongbridge, currently Xeris (Self: 3 financial relationships declared - Consulting Fees (e.g., advisory boards), Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Multicentric phase III trial); Tiburio (Self: 1 financial relationship declared - Consulting Fees (e.g., advisory boards))
• Anne T Sweeny, MD, FACE - Associate Professor of Medicine St. Elizabeth's Medical Center Brighton, MA: Nothing to disclose.
• Diane Donegan, MD - Associate Professor of Medicine Indiana University: Corcept (Self: 2 financial relationships declared - Consulting Fees (e.g., advisory boards), Contracted Research); Recordati (Self: 1 financial relationship declared - Consulting Fees (e.g., advisory boards))
• Karel Pacak, MD, PhD, DSc, FACE - Chief of the Section on Medical Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development: Nothing to disclose.

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

• Michael Blake, MD
• Adriana G. Ioachimescu, MD, PhD, FACE
• Anne T. Sweeney, MD, FACE
• Diane Donegan, MD
• Karel Pacak, MD, PhD, DSc, FACE